Acumen Q1 net loss $11.3M; cash $183.8M; Phase 1 ACU193 topline due Q3 2023

Acumen Pharmaceuticals, Inc.

2023-Q1 EPS reported -$0.28

Net loss of $11.3M for Q1 2023 vs $9.1M in Q1 2022; no revenue reported.
Cash, equivalents and marketable securities $183.8M as of March 31, 2023, down from $193.4M at Dec 31, 2022.
R&D expenses $8.7M (up from $6.0M) driven by ongoing Phase 1 INTERCEPT-AD trial of ACU193.
Company expects to report topline Phase 1 data for ACU193 in early Alzheimer's in Q3 2023, with FDA interaction in Q4.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Acumen Pharmaceuticals, Inc. reported three months ended March 31, 2023 results: net income $11.3 million.

Period: three months ended March 31, 2023
Net income: $11.3 million
Result: reported results

Exact text from the filing

Net loss was $11.3 million for the three-month period ended March 31, 2023

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Acumen Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001576885-23-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.